SLC5A2 and Glycosuria: Patients receiving SGLT2 inhibitors have a compensatory increase in glucose intake that counteracts the negative energy balance caused by glycosuria (Horie et al., 2018), and the weight loss is mainly due to a reduction in fat deposition.